Pegaspargase, gemcitabine, dexamethasone, and cisplatin (P-GDP) combined chemotherapy is effective for newly diagnosed extranodal NK/T-cell lymphoma: a retrospective study.
Pegaspargase, gemcitabine, dexamethasone, and cisplatin (P-GDP) combined chemotherapy is effective for newly diagnosed extranodal NK/T-cell lymphoma: a retrospective study.
复制标题
培门冬酶、吉西他滨、地塞米松和顺铂 (P-GDP) 联合化疗对新诊断的结外 NK/T 细胞淋巴瘤有效：一项回顾性研究
DOI：
10.2147/cmar.s179567
复制
发表时间：
2018
影响因子：
3.3
通讯作者：
Zhang L
中科院分区：
文献类型：
--
作者：
Liu T;Zhu F;Xiao Y;Li Q;Liu X;Yang K;Wu G;Zhang L
l-天冬酰胺酶或pegaspargas为基础的化疗在治疗结外NK/ t细胞淋巴瘤方面显示出有希望的结果。一项回顾性研究旨在确定pegaspargase、吉西他滨、地塞米松和顺铂（P-GDP）联合化疗对新诊断的结外NK/ t细胞淋巴瘤患者的疗效和安全性。2013年9月至2016年11月，57例新诊断的I至IV期结外NK/ t细胞淋巴瘤患者接受了P-GDP化疗。收集并分析这些患者的临床资料，以评估P-GDP的有效性和安全性。所有患者均接受1-6个周期的P-GDP化疗，P-GDP方案的中位周期数为3个。总有效率为89.5%(51/57)，其中完全缓解率为70.2%(40/59)，部分缓解率为19.3%（11/57）。中位随访时间为28个月（2-54个月）。2年总生存率和无进展生存率（PFS）分别为82.9%和75.9%。对于I/II期和III/IV期患者，2年PFS分别为80.8%和66.7%。最常见的3/4级不良事件是中性粒细胞减少症（42.1%）、血小板减少症（38.6%）和低纤维蛋白原血症（26.3%）。未观察到与治疗相关的死亡。P-GDP联合化疗对新诊断的淋巴结外NK/ t细胞淋巴瘤鼻型患者是高效安全的。需要更多的大样本前瞻性试验来证实这些结果。
l-asparaginase or pegaspargase-based chemotherapies have shown promising results in the treatment of extranodal NK/T-cell lymphoma. A retrospective study was conducted to determine the efficacy and safety of pegaspargase, gemcitabine, dexamethasone, and cisplatin (P-GDP) combined chemotherapy in patients with newly diagnosed extranodal NK/T-cell lymphoma. From September 2013 to November 2016, 57 patients with newly diagnosed, stages I to IV, extranodal NK/T-cell lymphoma received P-GDP chemotherapy. Clinical data from these patients were collected and analyzed to evaluate the efficacy and safety of P-GDP. All patients were subjected to 1–6 cycles of P-GDP chemotherapy, and the median number of cycles of P-GDP regimen administered was 3. The overall response rate was 89.5% (51/57), including a complete response rate of 70.2% (40/59) and a partial response rate of 19.3% (11/57). The median follow-up time was 28 months (range 2–54 months). The 2-year overall survival and progression-free survival (PFS) rates were 82.9% and 75.9%, respectively. For stage I/II patients and stage III/IV patients, 2-year PFS were 80.8% and 66.7%, respectively. The most common grade 3/4 adverse events were neutropenia (42.1%), thrombocytopenia (38.6%), and hypofibrinogenemia (26.3%). No treatment-related deaths were observed. P-GDP combination chemotherapy is highly effective and safe for newly diagnosed patients with extranodal NK/T-cell lymphoma, nasal type. Additional large sample prospective trials are required to confirm these results.